Orasure Technologies (OSUR)
NASDAQ:OSUR
Want to see OSUR full AI Analyst Report?
Top Page
Orasure Technologies
(NASDAQ:OSUR)
Select Model
Select Model
Rating:54Neutral
Price Target:
$4.00
▲(68.07% Upside)
Action:Reiterated
Date:06/11/26
The score is held back primarily by weak financial performance (large losses and negative cash flow), partially offset by a strong balance sheet. Technicals are supportive with an uptrend across key moving averages and positive momentum indicators. The latest earnings call was balanced, with credible product/regulatory catalysts and margin progress, but ongoing losses and a multi-quarter timeline to cash-flow breakeven limit upside confidence. Valuation is less supportive given negative earnings and no dividend yield.
Positive Factors
FDA clearance — Colli‑Pee
FDA clearance establishes a durable commercial pathway for at‑home first‑void urine collection integrated with major lab platforms (Roche). This materially expands addressable markets for specimen collection, strengthens lab partnerships, and creates recurring kit demand as adoption of remote sampling grows.
Negative Factors
Negative operating cash flow
Sustained negative operating cash flow consumes cash reserves and limits reinvestment flexibility. If revenue ramps are delayed, the company may need to cut spend or seek financing, which could dilute shareholders or slow commercialization of strategic products slated to drive medium‑term recovery.
Read all positive and negative factors
Positive Factors
Negative Factors
FDA clearance — Colli‑Pee
FDA clearance establishes a durable commercial pathway for at‑home first‑void urine collection integrated with major lab platforms (Roche). This materially expands addressable markets for specimen collection, strengthens lab partnerships, and creates recurring kit demand as adoption of remote sampling grows.
Read all positive factors
Orasure Technologies (OSUR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$292.61M
Dividend YieldN/A
Average Volume (3M)771.42K
Price to Earnings (P/E)―
Beta (1Y)0.83
Revenue Growth-30.08%
EPS Growth-143.79%
CountryUS
Employees501
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)-1.04
Shares Outstanding68,848,560
10 Day Avg. Volume735,713
30 Day Avg. Volume771,421
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.52
Price to Sales (P/S)1.55
P/FCF Ratio-3.34K
Enterprise Value/Market Cap0.59
Enterprise Value/Revenue1.52
Enterprise Value/Gross Profit3.69
Enterprise Value/Ebitda-2.69
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.85
Revenue Forecast (FY)$119.68M
Orasure Technologies Business Overview & Revenue Model
Company Description
OraSure Technologies, Inc. and its affiliates are a global leader in the development, production, and commercialization of advanced oral fluid diagnostic solutions and specialized specimen collection tools, serving markets across the United States...
How the Company Makes Money
OraSure primarily makes money by selling diagnostic products and related components to distributors, healthcare providers, public health organizations, and other customers. Key revenue streams generally include: (1) sales of infectious disease dia...
Orasure Technologies Earnings Call Summary
Earnings Call Date:May 06, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 11, 2026
Earnings Call Sentiment Neutral
The call presented a balanced picture: positive execution on cost and manufacturing initiatives led to gross margin expansion and sequential diagnostics growth, a strong cash position and ongoing buybacks support financial flexibility, and two FDA-submitted products plus near-shoring progress are meaningful near- to mid-term growth catalysts. Offsetting these positives are substantial operating losses, negative operating cash flow, elevated near-term operating expenses (including nonrecurring charges), muted demand in some Sample Management end markets due to slow NIH funding, and execution/timing risks associated with product ramps and near-shoring monetization. Given the mix of encouraging operational progress and clear near-term financial and execution risks, the overall tone is balanced.Positive Updates
Revenue Above Guidance and Sequential Growth
Q1 total revenue of $27.9 million, which came in above the midpoint of guidance and grew 4% sequentially.
Negative Updates
Significant Operating Losses and Negative Operating Cash Flow
GAAP operating loss of $23.3 million and non-GAAP operating loss of $19.0 million in Q1. Operating cash flow was negative $14 million, with management projecting a return to breakeven operating cash flow only in 2027.
Read all updates
Q1-2026 Updates
Positive
Negative
Revenue Above Guidance and Sequential Growth
Q1 total revenue of $27.9 million, which came in above the midpoint of guidance and grew 4% sequentially.
Read all positive updates
Company Guidance
For Q2 2026 OraSure guided revenue of $27.0–$30.0 million (with a negligible amount from COVID‑19 testing) and said Q2 gross margin should be similar to Q1 (Q1 GAAP gross margin 42.3%, non‑GAAP 43.4%), with operating expense in the high‑$20 million range (excluding stock compensation) and expected to decline to the mid‑$20 million range in Q3; R&D is expected to taper in Q2–Q3, G&A to normalize beginning in Q3, and management anticipates mid‑year FDA clearances with product revenue ramping in H2 2026 and a return to breakeven operating cash flow in 2027 (Q1 operating cash flow was negative $14.0M). For context, Q1 revenue was $27.9M (+4% sequential), Diagnostics $16.9M (+12% seq) and Sample Management $9.1M (flat), Q1 GAAP operating loss was $23.3M (non‑GAAP loss $19.0M), cash and cash equivalents were $177M with zero debt, and the company repurchased $5M (1.8M shares) in Q1 and $20M (7.1M shares) over the last four quarters.Orasure Technologies Financial Statement Overview
Summary
Income Statement
26
Negative
Balance Sheet
74
Positive
Cash Flow
32
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 113.02M | 115.02M | 185.83M | 405.47M | 387.48M | 233.67M |
| Gross Profit | 46.35M | 48.20M | 76.23M | 179.42M | 148.44M | 117.60M |
| EBITDA | -63.70M | -56.96M | -6.83M | 76.16M | -1.68M | 2.37M |
| Net Income | -75.07M | -68.73M | -19.50M | 53.66M | -17.13M | -23.00M |
Balance Sheet | ||||||
| Total Assets | 379.17M | 403.17M | 479.66M | 482.85M | 444.18M | 460.99M |
| Cash, Cash Equivalents and Short-Term Investments | 176.96M | 199.28M | 267.76M | 290.41M | 110.85M | 153.04M |
| Total Debt | 40.47M | 13.20M | 14.60M | 13.50M | 12.55M | 12.27M |
| Total Liabilities | 65.84M | 62.34M | 69.32M | 52.17M | 79.75M | 80.46M |
| Stockholders Equity | 313.32M | 340.83M | 410.34M | 430.67M | 364.43M | 380.53M |
Cash Flow | ||||||
| Free Cash Flow | -47.88M | -53.22K | 23.58M | 131.28M | -111.11M | -83.50M |
| Operating Cash Flow | -43.19M | -49.02K | 27.37M | 141.58M | -47.20M | -35.38M |
| Investing Cash Flow | -8.09M | -6.81K | -39.03M | 66.15M | 21.09M | -5.50M |
| Financing Cash Flow | -22.27M | -16.94K | -4.18M | -3.02M | -3.83M | -2.82M |
Orasure Technologies Technical Analysis
Positive
2.38
Price Trends
3.47
Positive
3.20
Positive
2.98
Positive
Market Momentum
0.26
Positive
61.32
Neutral
72.20
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OSUR, the sentiment is Positive. The current price of 2.38 is below the 20-day moving average (MA) of 4.08, below the 50-day MA of 3.47, and below the 200-day MA of 2.98, indicating a bullish trend. The MACD of 0.26 indicates Positive momentum. The RSI at 61.32 is Neutral, neither overbought nor oversold. The STOCH value of 72.20 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for OSUR.
Orasure Technologies Risk Analysis
Orasure Technologies disclosed 66 risk factors in its most recent earnings report. Orasure Technologies reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Orasure Technologies Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | $213.46M | 19.68 | 9.13% | 2.15% | -4.43% | -10.66% | |
60 Neutral | $190.11M | 24.07 | 14.00% | ― | 3.50% | 157.81% | |
54 Neutral | $292.61M | -3.94 | -21.50% | ― | -30.08% | -143.79% | |
53 Neutral | $201.79M | -5.71 | -246.44% | ― | 17.41% | -189.91% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $183.74M | -8.58 | -153.21% | ― | 13.40% | 20.97% |
* Healthcare Sector Average
OSUR
Orasure Technologies
4.25
1.22
40.26%
INFU
InfuSystem Holdings
9.42
3.24
52.43%
STXS
Stereotaxis
1.88
-0.23
-10.90%
UTMD
Utah Medical Products
67.04
13.22
24.57%
MBOT
Microbot Medical
1.86
-0.50
-21.19%
SMTI
Sanara MedTech
22.02
-5.80
-20.85%
Orasure Technologies Corporate Events
Business Operations and StrategyProduct-Related Announcements
OraSure Wins FDA Clearance for At-Home STI Collection
Positive
Jun 11, 2026
On June 11, 2026, OraSure Technologies, Inc. announced that the U.S. FDA cleared its Colli-Pee Dx Urine Collection Kit from subsidiary DNA Genotek Inc. for use with Roche molecular tests for four sexually transmitted infections on Roche’s co...
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
OraSure Technologies Investors Approve Expanded Stock Plan, Governance Changes
Positive
Jun 3, 2026
At its June 3, 2026 annual meeting, OraSure Technologies’ stockholders approved an amendment and restatement of the company’s 2000 Stock Award Plan, increasing the pool of common shares available for equity grants by 5,000,000, a move ...
Business Operations and StrategyFinancial Disclosures
OraSure Technologies Reports First-Quarter 2026 Financial Results
Negative
May 6, 2026
On May 6, 2026, OraSure Technologies reported first-quarter 2026 results, posting total net revenues of $27.9 million, slightly below the prior year as COVID-19 and risk assessment testing revenues declined, but with core business sales essentiall...
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
OraSure, Altai Capital Reach Governance Cooperation Agreement
Positive
Apr 17, 2026
On April 16, 2026, OraSure Technologies announced a cooperation agreement with activist investor Altai Capital, under which Altai withdrew prior director nominations and stockholder proposals and agreed to customary standstill and voting provision...
Business Operations and StrategyStock Buyback
OraSure Defends Strategy Amid Activist Altai Governance Challenge
Positive
Mar 30, 2026
On March 30, 2026, OraSure Technologies released a presentation defending its performance and governance in response to activist investor Altai Capital’s push to replace two independent directors, highlighting that its shareholder returns ha...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.